A systematic review and network meta-analysis (NMA) was performed to evaluate the efficacy of first-line treatments for locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) patients. Databases were searched for randomized controlled trials evaluating first-line treatments for locally recurrent unresectable or metastatic TNBC patients. NMA was performed to estimate relative treatment effects on overall and progression-free survival between pembrolizumab + chemotherapy and other interventions. NMA including eight trials showed that the relative efficacy of pembrolizumab + chemotherapy was statistically superior to that of other immunotherapy- or chemotherapy-based treatment regimens. Pembrolizumab + chemotherapy confers benefits in survival outcomes versus alternative interventions for the first-line treatment of locally recurrent unresectable or metastatic TNBC patients.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457619PMC
http://dx.doi.org/10.2217/fon-2023-0301DOI Listing

Publication Analysis

Top Keywords

locally recurrent
12
recurrent unresectable
12
unresectable metastatic
12
tnbc patients
12
first-line treatment
8
triple-negative breast
8
breast cancer
8
nma performed
8
first-line treatments
8
treatments locally
8

Similar Publications

Introduction: Rhabdomyosarcoma (RMS) is a common pediatric orbital malignancy but is extremely rare in adults. This study assesses clinical and radiographic features, management, and outcomes in adult orbital RMS patients with comparison to pediatric patients.

Methods: A retrospective chart review from 2000-2023 at Bascom Palmer Eye Institute was conducted evaluating patients aged 0 to 100-years-old with biopsy-confirmed orbital RMS.

View Article and Find Full Text PDF

Massive Localized Lymphedema, Wound Care Without Major Surgical Excision: A Case Report.

Adv Skin Wound Care

January 2025

Danique Heuvelings, MD, is Medical Doctor and Surgical PhD Candidate, Department of Surgery, Maastricht University Medical Center, Maastricht, the Netherlands, and NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University. Also at Department of Surgery, Maastricht University Medical Center, Jishmaël van der Horst, MD, is Clinical Specialist, and Fanny Pelzer, MD, is Wound Care Nurse. Frits Aarts, MD, PhD, is Oncological Surgeon, Department of Surgery, VieCuri Medical Centre, Venlo, the Netherlands. Sanne Engelen, MD, PhD, is Oncological Surgeon, Department of Surgery, Maastricht University Medical Center.

Massive localized lymphedema (MLL) is a benign overgrowth of lymphoproliferative tissue that is primarily observed in adults with class III obesity. Patients present with a painless mass that has usually been present for a considerable period. Consultation of a healthcare professional typically takes place when MLL-related complaints interfere with daily living.

View Article and Find Full Text PDF

Background: Patients with transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) have limited treatment options and poor outcomes.

Methods: This phase III study (NCT04236141) evaluated the efficacy and safety of polatuzumab vedotin plus bendamustine and rituximab (Pola+BR) versus BR in Chinese patients with transplant-ineligible R/R DLBCL to support regulatory submission in China. Patients were randomized 2:1 to receive Pola+BR or placebo+BR.

View Article and Find Full Text PDF

Background: This study investigated the clinical efficacy and prognostic factors of ablative treatment in hepatocellular carcinoma (HCC) patients with and without diabetes mellitus (DM).

Methods: Retrospective data were collected from HCC patients who underwent ablation between January 2016 and December 2019. The baseline clinicopathological characteristics and long-term outcomes, such as overall survival (OS) and recurrence-free survival (RFS), were compared between those with and without DM.

View Article and Find Full Text PDF

Background: Endoscopic submucosal dissection (ESD) is a standardized procedure for intramucosal and slightly invasive submucosal colorectal cancers (CRC). However, the role of ESD for T1b (depth of submucosal invasion: ≥1,000 μm) CRC remains unclear. This study aimed to investigate the long-term efficacy and safety of ESD for T1b CRC.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!